特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
969253

呼吸器感染症診断市場:技術、プレックス、場所、地域別 - Covid-19の影響と予測/分析、エグゼクティブガイドおよびコンサルタントガイド(2021年~2025年)

Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with Covid-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 347 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
呼吸器感染症診断市場:技術、プレックス、場所、地域別 - Covid-19の影響と予測/分析、エグゼクティブガイドおよびコンサルタントガイド(2021年~2025年)
出版日: 2020年11月05日
発行: Howe Sound Research
ページ情報: 英文 347 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、世界の呼吸器感染症診断市場について調査しており、COVID-19の影響、市場の成長および抑制要因、開発動向、技術・プレックス・場所・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

I. 呼吸器感染症診断市場:戦略的状況分析とCOVID-19の影響

II. エグゼクティブ、マーケティング、セールス、ビジネス開発スタッフのためのガイド

III. 経営コンサルタントと投資顧問のためのガイド

第1章 イントロダクションと市場の定義

  • 呼吸器感染症とは何か?
  • 診断と治療の役割
  • 市場の定義
    • 収益市場規模
  • 調査手法
  • 臨床検査に関する支出の見通し

第2章 市場概要

  • 市場参入企業
    • 学術調査室
    • 診断検査開発者
    • 計装サプライヤー
    • ディストリビューターおよび試薬サプライヤー
    • 独立した検査ラボ
    • 公立国立/地域研究所
    • 病院ラボ
    • 医師のオフィスラボ
    • 監査機関
    • 認証機関
  • 呼吸器感染症
    • マーケティングへの影響
    • 肺炎の役割
    • 細菌感染症
    • 結核:特別な場合
    • ウイルス感染症
    • 真菌およびその他の病原体
  • 診断:変化する役割
    • 歴史的実践
    • 現在の診断
    • マルチプレックスベクトル
    • 将来の診断-いつどこでの問題
    • 呼吸器感染症の診断-目的地
    • 防御兵器としての診断
  • COVID-19
    • 徴候と症状
    • 伝染;感染
    • 診断
    • 防止
    • 管理
    • 予後
  • パンデミック診断
    • リスク管理:スパークアンドスプレッド
    • Dxテクノロジー:核酸ベース
    • Dxテクノロジー:イムノアッセイおよび血清学
    • 市場投入までの時間と準備の問題
    • パンデミック管理におけるマルチプレックスの認識されていない役割

第3章 市場動向

  • 市場成長要因
  • 市場抑制要因
  • 計装と自動化
  • 診断技術の開発

第4章 呼吸器感染症診断の最近の進展

  • 最近の進展-重要性とこのセクションの使用方法
    • これらの進展の重要性
    • このセクションの使用方法
      • GenMarkがSARS-CoV-2、呼吸器パネルの需要増加に対応
      • Tempusが大規模なCOVID-19検査、データイニシアチブを発表
      • Abacus Diagnostica Readying Multiplex 呼吸器検査
      • QiagenがNeuMoDx Molecularを買収
      • Dx企業のSARS-CoV-2、インフルエンザの多重検査への注目
      • Novacytがコロナウイルス、インフルエンザ、RSVコンボパネルのCEマークを取得
      • MammothBiosciencesがCRISPRベースの迅速なCOVID-19診断を発表
      • 結核検出のためのAIの開発、など

第5章 主要企業のプロファイル

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Co-Diagnostics
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Expedeon
  • Fusion Genomics
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veradus Labs
  • Veramarx

第6章 呼吸器感染症診断の世界市場

  • 国別:世界の市場概要
  • 技術別:世界の市場-概要
  • プレックス別:世界の市場-概要
  • 場所別:世界の市場-概要

第7章 世界市場:技術別

  • 微生物学
  • PCR
  • NGS
  • イムノアッセイ/その他
  • C19シングルプレックス

第8章 世界市場:プレックス別

  • C19シングルプレックス
  • シングルプレックス
  • デュプレックス/トリプレックス
  • マルチプレックステクノロジー

第9章 世界市場:場所別

  • 病院ラボ
  • 外来研究室
  • POC
  • その他

付録

  • 米国のメディケアシステム:2020年1月の臨床検査料金スケジュール
図表

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2020 ($million)
  • Table 2 Market Players by Type
  • Table 3 Bacterial Causes of Pneumonia
  • Table 4 List of Influenza Pandemics
  • Table 5 Viral Infections of the Respiratory Tract
  • Table 6 Fungal Infections of the Respiratory Tract
  • TABLE 7 CHARACTERISTICS OF CORONAVIRUS PANDEMIC INFECTIONS
  • TABLE 8 COVID-19 SYMPTOMS
  • Table 9 Five Factors Driving Growth
  • Table 10 Three Factors Limiting Growth
  • Table 11 Key Diagnostic Laboratory Technology Trends
  • Table 12 Long Term Pathoghen Identification Timetable
  • Table 13 - Global Market by Region
  • Table 14 Global Market by Technology
  • Table 15 Global Market by Plex
  • Table 16 Global Market by Place
  • Table 17 Microbiology by Country
  • Table 18 PCR by Country
  • Table 19 NGS by Country
  • Table 20 Immunoassay/Other by Country
  • Table 21 C19splex by Country
  • Table 22 C19 Single Plex by Country
  • Table 23 Singleplex by Country
  • Table 24 Duplex/Triplex by Country
  • Table 25 Multiplex by Country
  • Table 26 Hospital Lab by Country
  • Table 27 Outpatient Lab by Country
  • Table 28 POC by Country
  • Table 29 Other by Country
  • Table 30 2020 Laboratory Fee Schedule

Table of Figures

  • Figure 1 Upper vs. Lower Respiratory Tract
  • Figure 2 The LRI Mortality Rate Globally
  • Figure 3 Global Pandemic Pathogen Status
  • Figure 4 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 5 The BioFire Respiratory Panel
  • Figure 6 Pneumonia
  • Figure 7 Bacterial Infections of the Respiratory Tract
  • Figure 8 The Development Cycle of Tuberculosis
  • Figure 9 A Flu Epidemic in Europe - Historical Pattern
  • Figure 10 The Multiplex Paradigm Shift
  • Figure 11 Percentage of World Population Over 65
  • Figure 12 Global Market Share Chart
  • Figure 13 Global Market by Technology - Base vs. End Year
  • Figure 14 Global Market by Technology Base Year
  • Figure 15 Global Market by Technology End Year
  • Figure 16 Technology Share by Year
  • Figure 17 Plex - Base vs. End Year Segment Shift
  • Figure 18 Plex Market Base Year
  • Figure 19 Plex Market End Year
  • Figure 20 Plex Share by Year
  • Figure 21 Place - Base vs. End Year
  • Figure 22 Place Market Base Year
  • Figure 23 Place Market End Year
  • Figure 24 Place Share by Year
  • Figure 25 Microbiology Growth
  • Figure 26 PCR Diagnostics Growth
  • Figure 27 NGS Growth
  • Figure 28 Immunoassay/Other Growth
  • Figure 29 C19splex Growth
  • Figure 30 C19 Single Plex Growth
  • Figure 31 Singleplex Growth
  • Figure 32 Duplex/Triplex Growth
  • Figure 33 Multiplex Growth
  • Figure 34 Hospital Lab Growth
  • Figure 35 Outpatient Lab Growth
  • Figure 36 POC Growth
  • Figure 37 Other Growth
目次

OVERVIEW:

COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And lets not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician's Office Lab. Could the Home be next?

The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in depth report.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Respiratory Infections Diagnostic Market - Strategic Situation Analysis and Impact of COVID-19

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Respiratory Infections?
  • 1.2 The Role of Diagnosis & Treatment
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1 An Historical Look at Clinical Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Instrumentation Supplier
    • 2.1.4 Distributor and Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Office Labs
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Respiratory Infections
    • 2.2.1 Upper vs. Lower - Marketing Implications
    • 2.2.2 Understanding the Role of Pneumonia
    • 2.2.3 Bacterial Infections
      • 2.2.3.1 Streptococcal Infections
      • 2.2.3.2 Acute Otitis Media
      • 2.2.3.3 Bacterial Rhinosinusitis
      • 2.2.3.4 Diphtheria
      • 2.2.3.5 Pneumococcal Pneumonia
      • 2.2.3.6 Haemophilus Pneumonia
      • 2.2.3.7 Mycoplasma Pneumonia (Walking Pneumonia)
      • 2.2.3.8 Chlamydial Pneumonias and Psittacosis
      • 2.2.3.9 Health Care-Associated Pneumonia
      • 2.2.3.10 Pseudomonas Pneumonia
      • 2.2.3.11 Pertussis (Whooping Cough)
      • 2.2.3.12 Legionnaires Disease
    • 2.2.4 Tuberculosis - A Special Case
    • 2.2.5 Viral Infections
      • 2.2.5.1 The Common Cold
      • 2.2.5.2 Influenza
      • 2.2.5.3 Viral Pneumonia
      • 2.2.5.4 SARS and MERS
      • 2.2.5.5 Measles (Rubeola)
      • 2.2.5.6 Rubella (German Measles)
      • 2.2.5.7 Chickenpox and Shingles
    • 2.2.6 Fungal and Other Pathogens
      • 2.2.6.1 Histoplasmosis
      • 2.2.6.2 Coccidioidomycosis
      • 2.2.6.3 Blastomycosis
      • 2.2.6.4 Mucormycosis
      • 2.2.6.5 Aspergillosis
      • 2.2.6.6 Pneumocystis Pneumonia
      • 2.2.6.7 Cryptococcosis
  • 2.3 Diagnostics - A Changing Role
    • 2.3.1 Historical Practice
    • 2.3.2 Current Diagnostics
    • 2.3.3 The Multiplex Vector
    • 2.3.4 Future Diagnostics - The Question of When and Where
    • 2.3.5 Respiratory Infection Diagnostics - The Destination
    • 2.3.6 Diagnostics as Defensive Weapons
  • 2.4 COVID-19
    • 2.4.1 Signs and symptoms
    • 2.4.2 Transmission
    • 2.4.3 Diagnosis
    • 2.4.4 Prevention
    • 2.4.5 Management
    • 2.4.6 Prognosis
  • 2.5 Pandemic Diagnostics
    • 2.5.1 Risk Management - Spark and Spread
    • 2.5.2 Dx Technology - Nucleic Acid Based
    • 2.5.3 Dx Technology - Immunoassay & Serology
    • 2.5.4 Time to Market and Preparedness Issues
    • 2.5.5 Unrecognized Role of Multiplex in Pandemic Mangement

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Syndromic Multiplexing
    • 3.1.2 T.A.T
    • 3.1.3 Antimicrobial Resistance Movement
    • 3.1.4 Pandemic Mitigation
    • 3.1.5 An Aging at Risk Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 The Cost Curve
    • 3.2.2 Regulation and coverage
    • 3.2.3 Laissez Faire
  • 3.3 Instrumentation and Automation
    • 3.3.1 The Shrinking Multiplexing Machine
    • 3.3.2 Bioinformatics Networking and Anonymous Reporting
  • 3.4 Diagnostic Technology Development
    • 3.4.1 The Key Role of Time to Result
    • 3.4.2 Single Cell Genomics Changes the Picture
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 Pathogen Identification - A Projected Timetable of the Future

4. Respiratory Infection Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • GenMark to Meet Pent Up Demand for SARS-CoV-2, Respiratory Panel
      • Tempus Announces Large-Scale COVID-19 Testing, Data Initiative
      • Abacus Diagnostica Readying Multiplex Respiratory Test
      • Qiagen Acquires NeuMoDx Molecular
      • Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza
      • Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel
      • Cepheid Debuts 10-Color Technology With New Tuberculosis Test
      • BioMérieux's Pneumonia Panel Could Improve Care
      • Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
      • Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
      • Qiagen Respiratory Panel with Coronavirus Receives CE Mark
      • Lumos Diagnostics Closes $15M Series A Funding
      • Fusion Genomics Wins $1M to Assess NGS-Based Respiratory Tract Infection Assay
      • Coronavirus Detection Test Development by Co-Diagnostics
      • Rapid Diagnostics Completes Asset Purchase of Enigma Diagnostics
      • Flu-Like Epidemic Could Kill 80 Mn Globally
      • Startup developing AI for TB detection
      • Nipah Virus a Global Threat
      • Novacyt S.A.: New Molecular Respiratory Panel Ready for US Market
      • New DRC Ebola cases confirmed as FDA OKs rapid test
      • CE Mark for Smartphone-based Diagnostic Test for Adult Respiratory Disease
      • Curetis Submits Lower Respiratory Tract Infection Test for FDA Clearance
      • New rapid test diagnoses pneumonia and other lower respiratory infections
      • Ontera Awarded Contract for Zika Genotyping Test
      • Two New Members Join Global Diagnostics Network
      • BARDA Funding Health Security Solutions

5. Profiles of Key Players

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Co-Diagnostics
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Expedeon
  • Fusion Genomics
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veradus Labs
  • Veramarx

6. The Global Market for Respiratory Infection Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Technology - Overview
    • 6.2.1 Table - Global Market by Technology
    • 6.2.2 Chart - Global Market by Technology - Base/End Year Comparison
    • 6.2.3 Chart - Global Market by Technology - Base Year
    • 6.2.4 Chart - Global Market by Technology - End Year
    • 6.2.5 Chart - Global Market by Technology - Share by Year
  • 6.3 Global Market by Plex - Overview
    • 6.3.1 Table - Global Market by Plex
    • 6.3.2 Chart - Global Market by Plex - Base/End Year Comparison
    • 6.3.3 Chart - Global Market by Plex - Base Year
    • 6.3.4 Chart - Global Market by Plex - End Year
    • 6.3.5 Chart - Global Market by Plex - Share by Year
  • 6.4 Global Market by Place - Overview
    • 6.4.1 Table - Global Market by Place
    • 6.4.2 Chart - Global Market by Place - Base/End Year Comparison
    • 6.4.3 Chart - Global Market by Place - Base Year
    • 6.4.4 Chart - Global Market by Place - End Year
    • 6.4.5 Chart - Global Market by Place - Share by Year

7. Global Respiratory Infection Diagnostic Markets - By Technology

  • 7.1 Microbiology
    • 7.1.1 Table Microbiology - by Country
    • 7.1.2 Chart - Microbiology Growth
  • 7.2 PCR
    • 7.2.1 Table PCR - by Country
    • 7.2.2 Chart - PCR Growth
  • 7.3 NGS
    • 7.3.1 Table NGS - by Country
    • 7.3.2 Chart - NGS Growth
  • 7.4 Immunoassay/Other
    • 7.4.1 Table Immunoassay - by Country
    • 7.4.2 Chart - Immunoassay/Other Growth
  • 7.5 C19 Singleplex
    • 7.5.1 Table C19splex - by Country
    • 7.5.2 Chart - C19splex Growth

8. Global Respiratory Infection Diagnostic Markets - by Plex

  • 8.1 C19 Single Plex
    • 8.1.1 Table C19 Single Plex - by Country
    • 8.1.2 Chart - C19 Single Plex Growth
  • 8.2 Singleplex
    • 8.2.1 Table Singleplex - by Country
    • 8.2.2 Chart - Singleplex Growth
  • 8.3 Duplex/Triplex
    • 8.3.1 Table Duplex/Triplex - by Country
    • 8.3.2 Chart - Duplex/Triplex Growth
  • 8.4 Multiplex Technology
    • 8.4.1 Table Multiplex - by Country
    • 8.4.2 Chart - Multiplex Growth

9. Global Respiratory Infection Diagnostic Markets - by Place

  • 9.1 Hospital Lab
    • 9.1.1 Table Hospital Lab - by Country
    • 9.1.2 Chart - Hospital Lab Growth
  • 9.2 Outpatient Lab
    • 9.2.1 Table Outpatient Lab - by Country
    • 9.2.2 Chart - Outpatient Lab Growth
  • 9.3 POC
    • 9.3.1 Table POC - by Country
    • 9.3.2 Chart - POC Growth
  • 9.4 Other Technology
    • 9.4.1 Table Other - by Country
    • 9.4.2 Chart - Other Growth

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.